^
    Back
    Association details:
    Biomarker:EGFR wild-type
    Cancer:Non Small Cell Lung Cancer
    Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Exploratory clinical study of apatinib mesylate tablets in the treatment of EGFR negative patients with non squamous non-small cell lung cancer.

    Excerpt:
    ...after EGFR mutation detection was confirmed as EGFR mutation negative (EGFR wild type); 5. ...
    Trial ID:
    ChiCTR-OPC-16009894
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

    Excerpt:
    ...Histologically/cytologically confirmed advanced/metastatic lung adenocarcinoma of stage IV with documented wild-type EGFR; 6....
    Trial ID:
    NCT02691871
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

    Excerpt:
    ......
    Trial ID:
    ANSWER
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

    Excerpt:
    ...- Wild type of epidermal-growth-factor receptor (EGFR)....
    Trial ID:
    NCT02733107
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study

    Excerpt:
    ...Patients with wild type EGFR/ALK must received two kinds of systemic chemotherapy before；Patients with EGFR mutation positive had experienced treatment failure with TKI in first line and Chemotherapy in second line ； 4....
    Trial ID:
    NCT03594682
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

    Excerpt:
    ...Histologically or cytologically confirmed of lung adenocarcinoma, EGFR wild-type or known drug-resistant mutation, stage IV or irradiative stage IIIB....
    Trial ID:
    NCT03376737
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

    Excerpt:
    ...Histologically or pathologically confirmed non-squamous EGFR wild-type, ALK-rearrangement negative, stage IV non-small cell lung cancer(NSCLC)....
    Trial ID:
    NCT03201146
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

    Excerpt:
    ...- EGFR mutation detection confirmed EGFR mutation negative (EGFR wild-type)...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A clinical trial for apatinib combination with nab-paclitaxel /cisplatin in the treatment of NSCLC

    Excerpt:
    ...Histological or cytologic confirmed wild type of epidermal-growth-factor receptor (EGFR); 5. ...
    Trial ID:
    ChiCTR1900023657
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Prospective, single-center, observational clinical study for Camrelizumab in the second-line treatment of advanced EGFR and ALK wild-type non-small cell lung cancer

    Excerpt:
    ...EGFR and ALK wild-type non-small cell lung cancer patients by genetic testing; 5. ...
    Trial ID:
    ChiCTR1900027220
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    The prospective and open phase II clinical trial of whole brain radiotherapy combined with anti-angiogenesis therapy for wild-type EGFR non-squamous NSCLC with multiple brain metastases

    Excerpt:
    ...Patients are EGFR mutation negative(wild-type EGFR) confirmed by EGFR mutation detection(ARMS); 4. ...
    Trial ID:
    ChiCTR1800015196
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncotarget
    Title:

    Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR

    Published date:
    01/23/2018
    Excerpt:
    We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016....6 patients obtained partial response, and 21 showed stable disease. The ORR and DCR were 16.7% and 75%, respectively. The median PFS and OS were 4.5 months and 8.2 months, respectively....Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type...
    DOI:
    10.18632/oncotarget.23612